Glaxo Wellcome has handed PR for the UK launch of a new diabetes
product Romozin (troglitazone) to Manning Selvage and Lee, following a
The campaign,which is believed to carry a six-figure fee, will target
general practitioners and healthcare professionals through the medical
press and the medical and science pages of the national press.
MS&L will be responsible for launching the product and helping to
re-establish Glaxo Wellcome in the diabetes field.
’Glaxo were involved in the diabetes field in the 1970s as an insulin
supplier, but it has little presence at the moment,’ said a Glaxo
Romozin, the first of a new class of drugs, treats non-insulin dependent
diabetes mellitus. ’If you don’t treat non-insulin dependent diabetes
properly there are a lot of related problems, like heart disease,
amputations and obesity,’ said Henrietta Noyes, director of healthcare
’The main message stems from Glaxo Wellcome’s belief that diabetes is an
under-estimated illness,’ said the Glaxo spokesman.